MAGE-2 (157-166)

MAGE-2 (157-166) is a synthetic peptide fragment derived from the melanoma-associated antigen family, specifically corresponding to amino acid residues 157 through 166 of the MAGE-2 protein. As a member of the MAGE (Melanoma Antigen Gene) family, this peptide serves as a valuable tool for investigating antigen processing, immune recognition, and protein-protein interactions within the context of tumor immunology and cellular signaling pathways. Its defined sequence and biochemical properties make it particularly useful in research settings focused on elucidating the molecular mechanisms of antigen presentation and T-cell epitope mapping, as well as in the development of immunological assays.

Epitope Mapping: Researchers utilize MAGE-2 (157-166) to identify and characterize T-cell epitopes involved in immune recognition of tumor-associated antigens. By synthesizing this peptide and employing it in binding assays, investigators can determine the specificity and affinity of major histocompatibility complex (MHC) molecules for the antigenic sequence. This approach aids in dissecting the molecular basis of immune surveillance and contributes to the broader understanding of antigen processing pathways relevant to cancer immunology.

Immunological Assays: The peptide is frequently incorporated into in vitro assays designed to assess cellular immune responses, such as enzyme-linked immunospot (ELISPOT) and cytotoxic T lymphocyte (CTL) activation studies. By serving as a defined antigenic stimulus, it enables the quantification of peptide-specific T-cell populations and facilitates studies on T-cell receptor (TCR) recognition dynamics. This application is instrumental for evaluating immune competence and for screening the immunogenic potential of candidate epitopes in preclinical research settings.

Protein-Protein Interaction Studies: MAGE-2 (157-166) provides a model system for examining the interaction dynamics between antigenic peptides and their binding partners, including MHC class I molecules and TCRs. Utilizing this peptide in structural and biochemical assays, such as surface plasmon resonance or co-crystallization experiments, allows for detailed analysis of binding affinities, conformational changes, and the structural determinants underlying peptide-mediated recognition events.

Peptide-Based Vaccine Research: In the context of experimental immunotherapy development, the MAGE-2 (157-166) peptide is employed as a prototype antigen for evaluating peptide-based vaccine formulations. By incorporating it into immunization protocols in animal models or in vitro systems, scientists can monitor the induction of antigen-specific immune responses and optimize adjuvant combinations or delivery strategies. These studies are essential for advancing the rational design of next-generation immunotherapeutic agents targeting tumor-associated antigens.

Analytical Method Development: The defined sequence of this peptide makes it a valuable standard or reference material in the calibration and validation of mass spectrometry, high-performance liquid chromatography (HPLC), and other analytical platforms. Its use as a control or spike-in reagent supports the development of sensitive and specific detection methods for antigenic peptides in complex biological samples, thereby enhancing the accuracy and reproducibility of quantitative proteomic workflows.

1. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

2. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide

3. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

4. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

5. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes